There have been many reviews of the cyclic oligosaccharide cyclodextrin (CD) and CDbased materials used for drug delivery, but the capacity of CDs to complex different agents and their own intrinsic properties suggest they might also be considered for use as active drugs, not only as carriers. The aim of this review is to summarize the direct use of CDs as drugs, without using its complexing potential with other substances. The direct application of another oligosaccharide called cyclic nigerosyl‐1,6‐nigerose (CNN) is also described. The review is divided into lipid‐related diseases, aggregation diseases, antiviral and antiparasitic activities, anti‐anesthetic agent, function in diet, removal of organic toxins, CDs and collagen, cell differentiation, and finally, their use in contact lenses in which no drug other than CDs are involved. In the case of CNN, its application as a dietary supplement and immunological modulator is explained. Finally, a critical structure– activity explanation is provided.

Cyclic oligosaccharides as active drugs, an updated review

Matencio A.;Caldera F.;Cecone C.;Trotta F.
2020-01-01

Abstract

There have been many reviews of the cyclic oligosaccharide cyclodextrin (CD) and CDbased materials used for drug delivery, but the capacity of CDs to complex different agents and their own intrinsic properties suggest they might also be considered for use as active drugs, not only as carriers. The aim of this review is to summarize the direct use of CDs as drugs, without using its complexing potential with other substances. The direct application of another oligosaccharide called cyclic nigerosyl‐1,6‐nigerose (CNN) is also described. The review is divided into lipid‐related diseases, aggregation diseases, antiviral and antiparasitic activities, anti‐anesthetic agent, function in diet, removal of organic toxins, CDs and collagen, cell differentiation, and finally, their use in contact lenses in which no drug other than CDs are involved. In the case of CNN, its application as a dietary supplement and immunological modulator is explained. Finally, a critical structure– activity explanation is provided.
2020
13
10
1
20
Cyclic nigerosyl‐1,6‐nigerose; Cyclodextrins; Drug; Intrinsic; Review; Treatment
Matencio A.; Caldera F.; Cecone C.; Lopez-nicolas J.M.; Trotta F.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1763462
Citazioni
  • ???jsp.display-item.citation.pmc??? 10
  • Scopus 22
  • ???jsp.display-item.citation.isi??? 19
social impact